Document is current

Article History

Received: 20 December 2024

Accepted: 10 February 2025

First Online: 25 March 2025

Declarations

:

: SM: Grants or contracts (to institution): AstraZeneca, Daiichi Sankyo, Duality Bio, Genentech, Nuvation, Seagen; consulting fees: AstraZeneca, Daiichi Sankyo, Duality Bio, Eli Lilly, Genentech, Gilead, GSK, Macrogenics; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca, Daiichi Sankyo, Seagen; support for attending meetings and/or travel: AstraZeneca, Daiichi Sankyo, Seagen. SZ, YX, SH: Employees of Daiichi Sankyo, Inc. DB, AS: Employees of Daiichi Sankyo Europe GmbH. KD: Employee of Daiichi Sankyo UK Ltd. ZM: Employee of AstraZeneca. WJ: Grants or contracts: AstraZeneca, Daiichi Sankyo; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: AstraZeneca, BMS, Daiichi Sankyo, Eisai, Lilly (France), MSD, Novartis, Pfizer, Roche, Seagen; support for attending meetings and/or travel: AstraZeneca, Chugai, Eisai, GSK, Lilly (France), Novartis, Pfizer, Pierre Fabre, Roche, Sanofi Aventis; participation on a Data Safety Monitoring Board or Advisory Board: AstraZeneca, BMS, Daiichi Sankyo, Eisai, Gilead, Lilly (France), MSD, Novartis, Pfizer, Roche, Seagen.

: All the results presented in this article are in aggregate form, and no personally identifiable information was used for this study. The data were de-identified and subject to obligations to prevent re-identification and protect patient confidentiality.